Trial Profile
A Randomized, Double Blind, Placebo- And Active-controlled, 4 Week, Multi-center, Parallel Group Study Assessing The Analgesic Effect, Safety And Tolerability Of PF-06372865 In Subjects With Chronic Low Back Pain Using Naproxen As Positive Control
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Darigabat (Primary) ; Naproxen
- Indications Back pain
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 01 Sep 2018 Status changed to discontinued due to trial futility as per results published in the Pain.
- 15 Oct 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov record.
- 14 Aug 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Nov 2015 to 1 Aug 2015.